OBI-992 Ranks Among World ADC Award Top 8, Stands Strong Among Global Pharma Giants Despite Missing Top Prize, Gains Global Recognition

Currently held in San Diego, USA, the 15th World ADC San Diego conference announced the 2024 World ADC Awards winners at 6 pm (US PST) on November 6. OBI Pharma’s novel anticancer drug, OBI-992, was shortlisted from over a thousand nominated candidates, earning a spot among the top eight contenders for the "2024 Most Promising Clinical Candidate" award. This year, the awards ultimately went to Daiichi Sankyo’s two ADC drugs, Raludotatug Deruxtecan (R-DXd) and Ifinatamab Deruxtecan (I-DXd). while OBI-992 ultimately fell short of winning, Dr. Heidi Wang, CEO of OBI Pharma, remarked that its place among the top eight contenders amidst fierce competition with major global pharmaceutical companies is a strong testament to OBI Pharma’s contributions in ADC development and an honor to be recognized on the international stage.